Trastuzumab emtansine, marketed under the brand name Kadcyla, is an antibody-drug conjugate indicated for the treatment of HER2-positive breast cancer and gastric cancer, according to the European Medicines Agency (EMA). Originally granted a centralized marketing authorization valid throughout the European Union, the therapy combines the monoclonal antibody trastuzumab with the chemotherapy agent DM1, linked together to deliver the cytotoxic drug directly to HER2-positive cancer cells.
Regulatory Approvals and Indications
The European Medicines Agency first approved Kadcyla for adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane. The indications for the therapy later expanded following clinical trial evaluations coordinated by developers and regulatory authorities. According to the U.S. Food and Drug Administration (FDA), the drug is also approved as an adjuvant treatment for patients with early HER2-positive breast cancer who have residual invasive disease after taxane-based chemotherapy and trastuzumab-based treatment.
For gastric cancer, regulatory bodies evaluated the drug’s efficacy in patients with HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction. Clinical evaluations demonstrated that antibody-drug conjugates target specific proteins on cancer cells, minimizing systemic exposure compared to conventional chemotherapy regimens.
Mechanism of Action
Kadcyla functions as a targeted therapy that bridges immunology and oncology. According to clinical data published by the National Cancer Institute, the trastuzumab component binds to the HER2 receptor on the surface of cancer cells, inhibiting cell proliferation and signaling pathways. At the same time, the linkage system delivers the maytansinoid DM1 payload directly inside the malignant cell.
Once the complex internalizes, the DM1 molecules disrupt microtubule assembly, leading to cell cycle arrest and apoptosis. This targeted delivery mechanism limits damage to surrounding healthy tissue, distinguishing antibody-drug conjugates from traditional broad-spectrum chemotherapy treatments.
Clinical Efficacy and Safety Profile
Data from landmark clinical trials, such as the EMILIA study published in the New England Journal of Medicine, established the efficacy of trastuzumab emtansine in extending progression-free survival for patients with metastatic breast cancer compared to standard combination treatments. Patients receiving the therapy experienced manageable adverse events, though clinical guidelines require monitoring for specific toxicities.
Common adverse reactions documented in prescribing information include thrombocytopenia, elevated liver enzymes, peripheral neuropathy, and fatigue. Healthcare providers regularly monitor complete blood counts and liver function tests during treatment cycles to manage potential side effects and adjust dosing schedules when necessary.
Related reading